Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting PI3K Signaling in Acute Lymphoblastic Leukemia
Vanessa Edna Sanchez, Cydney Nichols, Hye Na Kim, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 2, pp. 412-412
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway
Vasiliki Zoi, Athanassios P. Kyritsis, Vasiliki Galani, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1554-1554
Open Access | Times Cited: 27
Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer
Fatma M. Elmenier, Deena S. Lasheen, Khaled A.M. Abouzid
European Journal of Medicinal Chemistry (2019) Vol. 183, pp. 111718-111718
Closed Access | Times Cited: 109
Targeting CXCR4 in AML and ALL
Daniel Cancilla, Michael P. Rettig, John F. DiPersio
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 88
Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes
Eric Owusu Obeng, Isabella Rusciano, Maria Vittoria Marvi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2581-2581
Open Access | Times Cited: 70
The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process
Soudeh Ghafouri‐Fard, Atefe Abak, Farhad Tondro Anamag, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 137, pp. 111279-111279
Open Access | Times Cited: 58
Design and synthesis of phenylthiophosphoryl dichloride derivatives and evaluation of their antitumour and anti-inflammatory activities
Chunyun Xu, Na Yang, Hsiao‐Wei Yu, et al.
Frontiers in Chemistry (2025) Vol. 12
Open Access | Times Cited: 1
Combining Network Pharmacology, Molecular Docking and Experimental Validation to Explore the Effects and Mechanisms of Indirubin on Acute Lymphoblastic Leukemia
Lu Jin, Yinghui Guan, Xue Li, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 1083-1103
Open Access | Times Cited: 1
Pathogenesis of pediatric B‑cell acute lymphoblastic leukemia: Molecular pathways and disease treatments (Review)
Fang‐Liang Huang, En‐Chih Liao, Chia‐Ling Li, et al.
Oncology Letters (2020) Vol. 20, Iss. 1, pp. 448-454
Open Access | Times Cited: 64
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
Dima A. Sabbah, Rima Hajjo, Sanaa K. Bardaweel, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 3, pp. 141-158
Closed Access | Times Cited: 7
Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer
Yanan Zheng, Siyue Lou, Jun Lu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 7
Open Access | Times Cited: 6
Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)
Dima A. Sabbah, Rima Hajjo, Sanaa K. Bardaweel, et al.
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 10, pp. 877-892
Closed Access | Times Cited: 37
Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials
Bruno Toson, Isadora Serraglio Fortes, Rafael Roesler, et al.
Pharmacological Research (2022) Vol. 183, pp. 106403-106403
Open Access | Times Cited: 25
Molecular target: pan-AKT in gastric cancer
Byung Woog Kang, Ian Chau
ESMO Open (2020) Vol. 5, Iss. 5, pp. e000728-e000728
Open Access | Times Cited: 37
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome
Maria Juárez, Nieves Díaz, Geoffrey I. Johnston, et al.
Lara D. Veeken (2020) Vol. 60, Iss. 3, pp. 1364-1375
Open Access | Times Cited: 36
Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin αv in Glioblastoma Cells
Qi Yu, Weikun Xiao, Songping Sun, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 28
Hedgehog and PI3K/Akt/mTOR Signaling Pathways Involvement in Leukemic Malignancies: Crosstalk and Role in Cell Death
Mariaconcetta Sicurella, Marica Chiara, Luca M. Neri
Cells (2025) Vol. 14, Iss. 4, pp. 269-269
Open Access
Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer
Ashraf N. Abdalla, Waleed H. Malki, Amal Qattan, et al.
Molecules (2021) Vol. 26, Iss. 2, pp. 334-334
Open Access | Times Cited: 24
TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas
Siyue Lou, Fanli Zheng, Yongmei Tang, et al.
Life Sciences (2024) Vol. 347, pp. 122662-122662
Closed Access | Times Cited: 3
Leveraging altered lipid metabolism in treating B cell malignancies
Jae Woong Lee, Arya Mani, Min‐Jeong Shin, et al.
Progress in Lipid Research (2024) Vol. 95, pp. 101288-101288
Open Access | Times Cited: 3
Development of Multi-Target Chemometric Models for the Inhibition of Class I PI3K Enzyme Isoforms: A Case Study Using QSAR-Co Tool
Amit Kumar Halder, M. Natália D. S. Cordeiro
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 17, pp. 4191-4191
Open Access | Times Cited: 26
Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma
Sabah Akhtar, Tayyiba Akbar Ali, Ammara Faiyaz, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5002-5002
Open Access | Times Cited: 26
The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis
Yangjiong Xiao, Yang Yu, Pengcheng Jiang, et al.
Cellular Oncology (2020) Vol. 43, Iss. 4, pp. 669-680
Closed Access | Times Cited: 25
Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562
Nehad M. El‐Dydamony, Rana M. Abdelnaby, Rasha Abdelhady, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 895-911
Open Access | Times Cited: 16
The Antileukemic and Anti-Prostatic Effect of Aeroplysinin-1 Is Mediated through ROS-Induced Apoptosis via NOX Activation and Inhibition of HIF-1a Activity
Shou‐Ping Shih, Mei‐Chin Lu, Mohamed El‐Shazly, et al.
Life (2022) Vol. 12, Iss. 5, pp. 687-687
Open Access | Times Cited: 15
<p>Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia</p>
Andrea Visentin, Federica Frezzato, Filippo Severin, et al.
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 9679-9688
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top